Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of SHR3680 New vs Old Formulations
NCT04903158Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rezvilutamide in prostate cancer (PCa) (2 arms), sponsored by Hengrui. Primary endpoints: Relative Bioavailability (Fr) at 336 hours, Maximum Plasma Concentration (Cmax) at 336 hours and 2 more. Status: unknown.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04903158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903158.